2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo group
2015
Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease
Friedman DJ, Singh JP, Curtis JP, Tang WHW, Bao H, Spatz ES, Hernandez AF, Patel UD, Al-Khatib SM. Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. Journal Of The American College Of Cardiology 2015, 66: 2618-2629. PMID: 26670062, DOI: 10.1016/j.jacc.2015.09.097.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac Resynchronization TherapyComorbidityComparative Effectiveness ResearchDefibrillators, ImplantableElectric CountershockFemaleGlomerular Filtration RateHeart FailureHospitalizationHumansMaleMedicareProportional Hazards ModelsRenal Insufficiency, ChronicSeverity of Illness IndexSurvival AnalysisTreatment OutcomeUnited StatesConceptsSevere chronic kidney diseaseChronic kidney diseaseCardiac resynchronization therapyCRT-eligible patientsHF hospitalizationKidney diseaseNational Cardiovascular Data Registry ICD RegistryUse of CRTComparative effectivenessInverse probability-weighted analysisReal-world comparative effectivenessEnd-stage renal diseaseCox proportional hazards modelCRT-D useHeart failure hospitalizationAcceptable complication rateDevice-related complicationsProportional hazards modelFine-Gray modelCKD classCKD stageFailure hospitalizationHF patientsPrimary endpointSecondary endpoints
2004
Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. JAMA Internal Medicine 2004, 164: 1389-1394. PMID: 15249347, DOI: 10.1001/archinte.164.13.1389.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedBisoprololBradycardiaCarbazolesCarvedilolDizzinessFatigueFemaleFollow-Up StudiesHeart Conduction SystemHeart FailureHumansHypotensionMaleMetoprololMiddle AgedPropanolaminesRisk FactorsRisk Reduction BehaviorSeverity of Illness IndexStatistics as TopicTreatment FailureVentricular Dysfunction, LeftWithholding TreatmentConceptsBeta-blocker therapyHeart failureAdverse effectsLeft ventricular systolic dysfunctionBeta-blocker trialsCardiovascular adverse effectsChronic heart failureHeart Failure TrialVentricular systolic dysfunctionΒ-blocker therapyRisk of hypotensionLife-saving therapyRandom-effects modelHF hospitalizationCause mortalitySystolic dysfunctionCause withdrawalsFailure TrialRandomized trialsAbsolute riskElectronic searchPatientsMEDLINE databaseTherapyAbsolute increase